Hepatic Porphyrias
📧 Sign up to get email alerts when something new happens for Hepatic Porphyrias.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Longitudinal Study of the Porphyrias
This longitudinal clinical trial focuses on acute hepatic porphyrias and porphyria cutanea tarda and is currently recruiting.
-
EMA approval · 2025-05-08EMA Authorised: Givlaari (Givosiran) — Alnylam Netherlands B.V.
The European Medicines Agency authorised Givlaari (givosiran) for treatment of acute hepatic porphyrias, with orphan medicine status.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) [Phase 3]
Phase 3 trial evaluating givosiran (ALN-AS1) for acute hepatic porphyrias has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
A terminated Alnylam-sponsored study (INSIGHT-AHP) sought to characterize the prevalence of acute hepatic porphyrias among patients with cli…